Clinical trials: Chikungunya Virus Infections
Dengue, Chikungunya
Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic Use in West Africa
The differential and systematic diagnosis of malaria, dengue and chikungunya in patients with fever (≥38.5°C) of undetermined etiology would allow the identification of infection by these pathogens and thus limit the…
- Conditions
- Dengue, Chikungunya, Malaria
- Trial name
- NCT06257810
- Testing
- VIDAS® Dengue Antigen NS1, VIDAS® Anti-Dengue IgM, VIDAS® Anti-Dengue IgG, VIDAS® Anti-Chikungunya IgM and VIDAS® Anti-Chikungunya IgG, Standard of care practices
- Where
- 3 sites in Burkina Faso, Côte d’Ivoire
- Volunteers
- 804 people
- Sponsor
- BioMérieux
Chikungunya
Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine
Chikungunya vaccine is an inactivated virus vaccine. There will be three study arms and subjects will be vaccinated in a dose escalation manner.In each arm, vaccine will be administered on Day 1, Day 29, and Day 57.
- Trial name
- NCT04603131
- Testing
- Inactivated Chikungunya virus vaccine 20 mcg, Inactivated Chikungunya virus vaccine 30 mcg, Inactivated Chikungunya virus vaccine 10 mcg
- Where
- 4 sites in India
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
Arbovirus Infections
Spatial Repellents for Arbovirus Control
Dengue viruses are the most medically important arthropod-borne pathogens worldwide, with transmission occurring in most tropical and sub-tropical regions. An estimated 390 million infections occur yearly.
- Trial name
- NCT03553277
- Testing
- transfluthrin
- Where
- Peru
- Volunteers
- 18,240 people, healthy volunteers welcome
- Sponsor
- University of Notre Dame
Chikungunya Virus Infection
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724).
- Trial name
- NCT04838444
- Testing
- VLA1553
- Where
- 10 sites in United States
- Volunteers
- 363 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Chikungunya Fever
Effects of Auriculotherapy on Pain and Functional Capacity of Individuals With Chikungunya Fever
Chikungunya fever is an acute viral disease, transmitted by the mosquito (Aedes aegypti), that triggers pain and disabling rheumatic manifestations.
- Trial name
- NCT03090685
- Testing
- True auriculotherapy with seeds
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Universidade Federal do Ceara
Clinical Syndrome
Oral Ivermectin for Chikungunya Viral Infection
Chikungunya viral infection (CVI) is a mosquito-borne infection, caused by chikungunya virus (CHIKV), an alphavirus, belonging to the family Togaviridae.
- Trial name
- NCT06259383
- Testing
- Ivermectin
- Where
- Thailand
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Prince of Songkla University
Arbovirus Infections
The Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return Travelers
International travel has increased dramatically in recent years. Vector-borne pathologies such as malaria and arboviruses are common etiologies of post-travel fever, which are prevalent in similar geographical areas (tropical and…
- Trial name
- NCT06651372
- Testing
- The retrospective analyses planned for these samples consist of serological analysis and molecular analysis (RT-PCR ) according to the date of symptoms ons
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Dengue Fever
Investigating Vector-Borne Determinants of Aedes Transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in Children
Background: Some mosquitos carry viruses that can cause disease. Some examples are dengue and Zika. The mosquitos spread disease by biting people and infecting them with the virus.
- Trial name
- NCT03534245
- Where
- Cambodia
- Volunteers
- 775 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease, Malaria
Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC
A mobile suitcase laboratory for EBOV point-of-care (POC) detection at Ebola treatment centers was successfully implemented in Guinea during the large Ebola virus disease (EVD) outbreak in West-Africa 2014-2015.
- Conditions
- Ebola Virus Disease, Malaria, Typhoid Fever, Dengue Fever
- Trial name
- MobEboDRC (NCT04235361)
- Testing
- Differential RPA tests
- Where
- 4 sites in Canada, Democratic Republic of the Congo and 2 more
- Volunteers
- 500 people
- Sponsor
- University of Stirling
Chikungunya Virus Infection
Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine
The purpose of this study is to evaluate the immunogenicity and safety of a novel vaccine against Chikungunya virus after one or two vaccinations by comparison of two different dose levels.
- Trial name
- MV-CHIK-202 (NCT02861586)
- Testing
- MV-CHIK low dose, MV-CHIK high dose, Priorix®
- Where
- 4 sites in Austria, Germany
- Volunteers
- 263 people, healthy volunteers welcome
- Sponsor
- Themis Bioscience GmbH
Chikungunya Virus
An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults
Study EBSI-CV-317-007 is a field study to evaluate the efficacy, immunogenicity, and safety of CHIKV VLP vaccine. The study was designed using infectious disease models and advanced analytics to guide region and clinical site…
- Trial name
- NCT07467707
- Testing
- CHIKV VLP vaccine
- Where
- 3 sites in Philippines, Thailand
- Volunteers
- 6,144 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Chikungunya Virus, Dengue Virus
A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components
The rationale for a Treatment Use Investigational Device Exemption (IDE) of INTERCEPT PCs is to address current gaps in platelet transfusion safety in selected geographic regions.
- Trial name
- TRUE (NCT02305732)
- Testing
- INTERCEPT Platelets
- Where
- 8 sites in Puerto Rico
- Volunteers
- 90 people
- Sponsor
- Cerus Corporation
Dengue, Chikungunya Virus Infection
Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Study setting: Medellin and Bello municipalities, Colombia Health condition(s) studied: Dengue, Zika and chikungunya virus infection Intervention: Deployment of Wolbachia-infected Aedes aegypti mosquitoes in Medellin and Bello.
- Conditions
- Dengue, Chikungunya Virus Infection, Zika Virus Infection
- Trial name
- WMP-COL (NCT03631719)
- Testing
- Wolbachia-carrying Ae.aegypti mosquitoes
- Where
- Colombia
- Volunteers
- 834 people
- Sponsor
- Universidad de Antioquia
Dengue, Chikungunya
Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.
This randomized, controlled, double blind trial aims at assessing the safety and immunogenicity profiles of the co-administered Live Attenuated Dengue and Chikungunya vaccines comparatively to the isolated administration, in the…
- Trial name
- NCT06973772
- Testing
- DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555)
- Where
- 7 sites in Brazil
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Chikungunya Fever, Chikungunya Virus
Trial of an Inactivated Chikungunya Virus Vaccine
This trial will be a randomized, placebo controlled, double-blind (within dosing group), dose escalation Phase 1 trial, evaluating dosages of 2.5 mcg and 8 mcg of HydroVax-005 CHIKV vaccine given intramuscularly on Day 1 and Day…
- Conditions
- Chikungunya Fever, Chikungunya Virus, Chikungunya
- Trial name
- NCT06669208
- Testing
- HydroVax-005 CHIKV
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Najit Technologies, Inc.
Chikungunya Virus Infection
Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
This is a cross-sectional serosurvey using household cluster sampling conducted before the VLA1553 pilot vaccination strategy will be implemented in about 10 municipalities in Brazil.
- Trial name
- NCT07163845
- Testing
- Live-attenuated CHIKV vaccine VLA1553
- Where
- 4 sites in Brazil
- Volunteers
- 5,354 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Chronic Pain Management, Chronic Pain and Comorbid Emotional Problems
EFFECT OF TRANSCUTANEOUS ELECTRONEURO-STIMULATION OF THE VAGUS NERVE ON JOINT PAIN SEQUELAE OF CHIKUNGUNYA FEVER IN THE LOWER LIMBS
This study aims to evaluate the efficacy of transcutaneous electrical nerve stimulation (taVNS) in reducing chronic lower limb joint pain in individuals with sequelae of Chikungunya fever.
- Trial name
- NCT07523126
- Testing
- Transcutaneous vagus nerve electrical stimulation, Transcutaneous eletrical nerve stimuation, Transcutaneous electrical nerve stimulation
- Where
- Brazil
- Volunteers
- 51 people
- Sponsor
- Universidade Federal de Pernambuco
Chikungunya Virus Infection
Consequences of a Maternal-fetal Chikungunya Virus Infection
Chikungunya is an infectious disease caused by an alphavirus transmitted by the Aedes mosquitoes which has known a worldwide expansion since its re-emergence in 2004.
- Trial name
- CHIK13+ (NCT04909411)
- Testing
- OPHTHALMOLOGICAL ASSESSMENT, NEUROPSYCHOLOGICAL ASSESSMENT
- Where
- Reunion
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Dengue Fever
A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue)
This is a cluster randomized controlled trial (CRCT) to evaluate the efficacy of Wolbachia-infected A. aegypti mosquito releases in reducing the burden of ARBV infection in Brazil over four years.
- Trial name
- NCT04514107
- Testing
- Brazilian National Dengue Control Program, Wolbachia-infected Aedes aegypti
- Where
- Brazil
- Volunteers
- 5,757 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Zika Virus Disease (Disorder), Dengue
The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico
This study will evaluate subjects with fever and/or rash to determine the percentage of those infected by the Zika, Chikungunya, or Dengue virus.
- Conditions
- Zika Virus Disease (Disorder), Dengue, Chikungunya
- Trial name
- Zik01 (NCT02831699)
- Where
- 6 sites in Mexico
- Volunteers
- 600 people
- Sponsor
- Mexican Emerging Infectious Diseases Clinical Research Network